OncoCyte announces publication of data on VitaGraft Kidney

Oncocyte Corporation announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The test was able to distinguish between two prevalent causes of premature graft failure: biopsy-proven antibody-mediated rejection and recurrent IgA nephropathy. This is the first publication investigating this application of VitaGraft’s donor-derived cell-free DNA diagnostic technology for kidney transplant patients. The data was published as a paper in the peer-reviewed journal Kidney International Reports. This ongoing prospective, observational trial evaluated VitaGraft Kidney’s dd-cfDNA diagnostic technology as a tool to discriminate between recurrent IgAN and ABMR. In the study, VitaGraft Kidney demonstrated higher sensitivity and specificity for detection of ABMR over routine tests. Differentiating between recurring IgAN and ABMR could help physicians select the appropriate treatment for the patient more quickly, while potentially also avoiding unnecessary procedures and treatments. In the paper, the authors highlight the limited value of currently marketed tests for the identification of treatable early-stage ABMR and suggest that dd-cfDNA testing could be a useful longitudinal management tool.